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Table. Clinical outcomes after follow-up in both Groups
Clinical outcomes
Large
difference
group
(n=383)
Small
difference
group
(n=424)
Adjusted HR
(95% CI) p Value
Composite
end point*
38(10.0%) 27(6.4%) 1.712(1.043-2.809) 0.033
All-cause death 25(6.6%) 12(2.8%) 2.425(1.218-4.829) 0.012
Cardiac death 15(3.9%) 6(1.4%) 2.837(1.101-7.313) 0.031
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM(MACE) rate, deﬁned as death, Q-wave myocardial infarction, and target lesion
revascularization.
Results: Baseline clinical characteristics, including mean graft age (12077 vs.
13186 months, p¼0.14), were similar between groups, except for higher prevalence
of hypertension, chronic renal insufﬁciency and higher body mass index in the dia-
betic group. Among the 604 SVG lesions treated with DES, the angiographic and
procedural characteristics were well matched, except for the higher rate of distal
protection device use (32% vs. 29%, p¼0.007) in the diabetic group. The 1-year
MACE rate (21% vs. 15%, p¼0.12) and all-cause mortality rate (7.6% vs. 6.7%,
p¼0.86) were similar between the two groups. After adjustment for the relevant
clinical co-variables, diabetes was not associated with the composite end point.Nonfatal MI 6(1.6%) 11(2.6%) 0.664(0.242-1.822) 0.426
All-cause
death or MI
30(7.9%) 22(5.2%) 1.623(0.934-2.821) 0.086
Stroke 9(2.4%) 5(1.2%) 2.355(0.788-7.042) 0.125
TVR 14(3.7%) 7(1.7%) 2.476(0.998-6.144) 0.051
TLR 37(9.7%) 50(11.8%) 0.945(0.615-1.452) 0.796Conclusions: Unlike the results seen in de novo lesions, when DES are utilized in PCI
of SVG lesions, the presence of diabetes is no loner a discriminator of the short- and
long-term outcomes.
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Background: A few data were available regarding the association between percuta-
neous coronary intervention (PCI) with drug-eluting stent (DES) and blood pressure
(BP) variability for long-term clinical outcomes.
Methods: Total 994 consecutive patients undergoing PCI with DES from March 2003
to August 2007 were enrolled. We measured patients' BP in a routine ward envi-
ronment just before transferring to the cath lab and in the cath lab before arterial
puncture (ward-to-cath lab BP) and assessed the differences of systolic and diastolic
BP, and heart rate. The subjects were divided into 2 groups according to the differ-
ences of ward-to-cath lab systolic BP: high variability group (n¼383) as the absolute
difference > 20mmHg and low variability group (n¼424) as the absolute difference
 20mmHg. The primary outcome of interest was the composite of death, myocardial
infarction (MI), or stroke.
Results: In 807 patients (522 males, 6010 years), the mean differences of systolic
and diastolic BP, and heart rate were 26.518.9 and 11.810.2 mmHg and 10.18.9
beats/min, respectively. During follow-up of 1878864 days, composite rate of death,
MI, or stroke was higher in the high variability group than the low variability group
(10.2% vs. 6.4%; adjusted hazard ratio, 1.96; 95% conﬁdence interval, 1.14-3.38; Cox
p¼0.016). The rates of death or MI (7.8% vs. 5.2%, p¼0.09) and stroke (2.3% vs.
1.2%, p¼0.17) were also numerically higher in the high variability group, which did
not reach statistical signiﬁcance. However, there were no signiﬁcant differences in
clinical outcomes for the ward-to-cath lab variability of diastolic BP and heart rate.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: This result suggests the variability of ward-to-cath lab systolic BP may
contribute to the elevated adverse cardiovascular risk in patients undergoing PCI with
DES.
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Background: The thin-strut, everolimus-eluting, platinum chromium PROMUS
Element stent (Boston Scientiﬁc, Natick MA) has shown favorable outcomes at 1 and
2 years post-implantation in the treatment of de novo lesions in small vessels
(2.25mm to <2.5mm in baseline diameter) and long lesions (>24 to 34mm in
length), but longer-term follow-up has not been previously reported.
Methods: PLATINUM SV and LL are prospective, single-arm, multinational studies
that enrolled patients with angina pectoris or documented silent ischemia and one de
novo native coronary artery target lesion. PLATINUM SV enrolled 94 subjects with
baseline vessel diameter 2.25mm to <2.50mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24 to 34mm long with
reference diameter 2.50 to 4.25mm.
Results: Patients were predominantly male (SV: 72.3%, LL: 62.7%) and approxi-
mately one third had diabetes (SV: 42.6%, LL: 30.0%). The mean baseline vessel
diameter in SV was 2.040.26 mm, and mean lesion length in LL was 24.388.21
mm. The primary endpoint, 1-year target lesion failure (deﬁned as cardiac death,
myocardial infarction related to the target vessel, or ischemia-driven target lesion
revascularization), was 2.4% for SV and 3.2% for LL, signiﬁcantly less than the
prespeciﬁed performance goals of 21.1% for SV and 19.4% for LL (P<0.001 for
each). At 3 years, outcomes for 84 evaluable patients in the SV trial were 4 (4.6%)
TLFs, 2 (2.4%) TLRs, 2 (2.3%) cardiac deaths, 1 (1.1%) non-cardiac deaths, and 1
(1.2%) MI, with no ARC deﬁnite/probable ST events. Through 2-year follow-up in
95/100 patients in LL, there were 8 (8.8%) TLFs, 5 (5.2%) TLRs, 3 (3.6%) cardiac
deaths, 1 (1.0%) non-cardiac death, and no MIs or ARC deﬁnite/probable ST. Three-
year results for LL will be available at the time of the meeting.
Conclusions: The PROMUS Element stent has demonstrated low target lesion failure
and revascularization rates, and acceptable safety outcomes with longer-term follow-
up in patients with small vessels and long lesions. The three-year results from these
studies will be available for presentation for the ﬁrst time at TCT 2013.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B57
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